Nelarabine Injection

Category: Antineoplastic / Chemotherapy drug
Form: Injectable solution for intravenous (IV) administration

Uses:

• Primarily used to treat T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL), especially in cases that are refractory or have relapsed.

• Works as a targeted therapy for malignant T-cells.

Mechanism of Action:

• Nelarabine is a prodrug of arabinosylguanine (ara-G).

• Once inside T-cells, it is converted to ara-G triphosphate, which is incorporated into DNA during replication.

• This incorporation inhibits DNA synthesis, leading to cell death, particularly in rapidly dividing T-lymphocytes.

• It has selective toxicity toward T-cells rather than B-cells or other tissues.

Administration:

• Administered intravenously, usually as a short infusion over a set period.

• Dosing depends on body surface area, patient condition, and treatment protocol.

• Often given in multiple cycles, as defined by oncology protocols.

Side Effects:

• Hematologic: anemia, neutropenia, thrombocytopenia (low blood counts).

• Neurologic: peripheral neuropathy, dizziness, somnolence, rarely severe CNS toxicity.

• Gastrointestinal: nausea, vomiting, diarrhea.

• Other: fatigue, fever, headache, injection site reactions.

Precautions:

• Regular monitoring of blood counts and neurological status is essential.

• Patients with pre-existing neurological conditions or kidney impairment require dose adjustments.

• Risk of severe infections due to immunosuppression.

Summary:
Nelarabine is a chemotherapy drug specifically targeting T-cell malignancies. It works by disrupting DNA replication in T-lymphocytes, causing cell death. Administration is intravenous under strict medical supervision, and side effects mainly involve blood cell suppression and potential neurological issues.